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Abstract
Background: Coronary artery calcium score incrementally improves coronary risk prediction beyond
that provided by conventional risk factors. Limited information is available regarding rates of progression
of coronary calcification in women, particularly those with baseline scores above zero. Further,
determinants of progression of coronary artery calcification in women are not well understood. This study
prospectively evaluated rates and determinants of progression of coronary artery calcium score in a group
of healthy postmenopausal women.
Methods: We determined coronary calcium score by computed tomography and recorded demographic,
lifestyle and health characteristics of 914 postmenopausal women, a subset of those enrolled in the
Women's Health Initiative Observational Study. The 305 women with calcium score ≥10 Agatston units
at baseline were invited for repeat scan. This analysis includes the 94 women who underwent second
scans.
Results: Mean age of study participants was 65 ± 9 years (mean ± SD), body mass index was 26.1 ± 6.1
kg/m2, and baseline calcium score was 162 ± 220 Agatston units. Mean interval between scans was 3.3 ±
0.7 years. A wide range of changes in coronary calcium score was observed, from -53 to +452 Agatston
units/year. Women with lower scores at baseline had smaller annual increases in absolute calcium score.
Coronary calcium scores increased 11, 31 and 79 Agatston units/year among women with baseline calcium
score in the lowest, middle and highest tertiles. In multivariate analysis, age was not an independent
predictor of absolute change in coronary calcium score. Hydroxymethylglutaryl coenzyme A reductase
inhibitor (statin) use at baseline was a negative predictor (p = 0.015), whereas baseline calcium score was
a strong, positive predictor (p < 0.0001) of progression of coronary calcification.
Conclusion: Among postmenopausal women with coronary calcium score ≥ 10 Agatston units, rates of
change of coronary calcium score varied widely. In multivariate analysis, statin use was a negative
independent determinant, whereas baseline calcium score was a strong positive predictor of annual change
in coronary calcium score.
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Coronary calcium, assessed by computed tomography,
strongly and independently predicts coronary risk [1-3].
Age is by far the most potent determinant of calcium score
[4], although conventional risk factors also been associ-
ated with the extent of coronary calcification [4,5].
The rate of progression of coronary calcification appears
to further stratify risk [6,7], but reports have been limited
by sample size [8], retrospective design [6,8,9], inclusion
of individuals with baseline calcium scores of zero [9,10]
and limited interval between tomographic scans
[8,10,11]. Further, not all studies adjusted for use of
hydroxymethylglutaryl coenzyme A reductase inhibitors
(statins), which have been reported to attenuate progres-
sion [9,12,13].
Calcium scores differ in men and women [4], but progres-
sion of coronary calcification has not been reported by
gender, except for the Healthy Women Study, which only
included women [10]. Of the 80 women in that cohort, 52
(65%) had calcium scores of zero at baseline. After mean
follow up of 18 months, 47 of the 52 (90%) had no coro-
nary calcium on repeat scan. Mean change for the 52
women was 0.4 Agatston units and median change was 0.
Among the 28 women with measurable coronary calcium
at baseline, mean change was 11 Agatston units for
women with baseline calcium score 1–99, and 72 Agat-
ston units for the 9 women with baseline calcium score
≥100.
In this study, we prospectively assessed the rate of progres-
sion of coronary calcification in an ethnically diverse
group of healthy women with coronary calcium scores of
at least 10 Agatston units at baseline, and identified inde-
pendent predictors of progression.
Methods
Patient population
Study participants were a subset of women enrolled in the
Women's Health Initiative Observational Study [14] at
the George Washington University and Howard Univer-
sity/Medstar clinical sites between February 1995, and
December, 1998. Women who joined this ancillary study
provided informed consent in a form approved by the
respective institutional review boards.
The entire Observational Study cohort comprises 93,676
women at 40 clinical sites. For this ancillary study, partic-
ipants at the George Washington and Howard/Medstar
clinics (n = 4435) were invited for computed tomography.
Baseline scans were performed on the 914 women who
responded to the invitation. Of these, 528 had no coro-
nary calcium detected and 81 had calcium scores of 1 – 9
Agatston units. The remaining 305 women with calcium
score ≥10 Agatston units were mailed a letter inviting
them to have a second scan; African-American women
received two mailings because of a historically lower
response rate. This analysis includes the 94 women with
serial scans, which were performed a mean of 3.3 ± 0.7
years after the baseline study.
Variables
Participants provided data on a wide range of health vari-
ables including dietary habits, medical history and
anthropometric measures. Questionnaire measures
assessed self-reported hypertension, diabetes mellitus
(excluding gestational diabetes), current smoking, high
cholesterol requiring pills, postmenopausal hormone
therapy, and family history of premature coronary disease
(father with myocardial infarction at age 55 years or
younger, or mother with myocardial infarction at age 65
or younger). Statin use at baseline was assessed by medi-
cation inventory.
Dietary fat consumption was assessed using a food fre-
quency questionnaire based on instruments used in the
Women's Health Trial [15]. Nutrient estimates from the
food frequency questionnaire were similar to those from
short-term dietary recall and from four-day food records
[16].
Physical activity was assessed by questions on a frequency
and duration scale of four walking speeds and three other
types of activity classified by intensity (strenuous, moder-
ate or light)[17]. For this analysis, we categorized women
by the number of weekly episodes, at least 20 minutes in
duration, of moderate or strenuous activity.
Plasma lipids were only measured in a 1% random sub-
sample of Observational Study participants, so were not
included as variables in these analyses.
CT image acquisition and analysis
Images were acquired using an Imatron C – 150 scanner.
Thirty contiguous 3-mm slides (100 ms/slice) were
acquired during a single breathhold beginning 1 cm cau-
dad to the carina. Each level was triggered by ECG in end-
diastole (80% of R-R interval). Images were obtained with
a 30-cm2 field of view (pixel size, 0.586 mm). Images were
analyzed by the Agatson method [18].
Analysis
Descriptive statistics such as frequencies, percentages,
means and standard deviations (SD) were used to
describe the study population and to explore the relation-
ships between coronary calcium score and several explan-
atory variables. Group comparisons were made by t test,
chi square and, where appropriate, the Mantel-Hanzel chi
square test. In Table 2, the p value is based on rankedPage 2 of 6
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in coronary calcium score in Table 2 is adjusted for age
using ANCOVA's least squares means.
Determinants of annual change in calcium score were
evaluated in a multiple linear regression model which
included age, baseline calcium score, and statin use at
baseline as independent variables (Table 4). In a separate
model, hypertension was added. Age and statin use were
selected as independent variables because they have con-
sistently been identified as determinants of coronary cal-
cification [12,13,19]. Baseline calcium score and
hypertension were included because of their relationship
to change in calcium score in Table 2 and 3, respectively.
Analyses were carried out using SAS System for Windows
v8.02.
Results
Baseline demographic and health characteristics of the 94
women with serial scans are shown (Table 1). Among the
305 women with calcium score ≥10 Agatson units, charac-
teristics of the 94 women with a second scan were similar
to the 211 women without a second scan (data not
shown), except that the former group was enriched for
Table 1: Comparison of women with serial scans vs women with calcium score <10
Group A Group B
mean (SD) p value
N 94 609
Age, y 65 (9) 61 (8) <0.0001
Body mass index, kg/m2 26.1 (6.1) 25.9 (5.6) NS
Baseline calcium score, Agatston units 162 (220) 0.5 (1.6) <0.0001
% dietary calories from fat 27 (8) 26.5 (7.4) NS
BP, mm Hg
Systolic 126 (19) 119 (17) 0.001
Diastolic 75 (10) 73 (13) NS
No. (%)
Ethnicity <0.0001
White 58 (62%) 490 (80%)
Black 31 (33%) 88 (14%)
Asian/Pacific islander 3 (3%) 12 (2%)
Hispanic 1 (1%) 11 (2%)
Unknown 1 (1%) 8 (1%)
Hypertension* 41 (44%) 146 (24%) <0.0001
Diabetes mellitus 5 (5%) 7 (1%) 0.004
Current smoking 8 (9%) 24 (4%) <0.05
Self-reported high cholesterol requiring pills 20 (21%) 76 (12%) 0.02
Hormone use at baseline 42 (45%) 366 (60%) 0.005
Statin use at baseline 9 (10%) 51 (8%) <0.05
# days/week moderate/vigorous exercise 2.2 (2.3) 2.5 (2.4) NS
Group A, women with baseline calcium score ≥10 Agatston units and serial scans;
Group B, women with baseline calcium score <10
* Self-reported hypertension or measured BP systolic >140 or diastolic >90
Table 2: Annual change in calcium score
Baseline calcium score Annual change in calcium score
Unadjusted Age-adjusted % change
(Agatston units) (Agatston units/y)
mean (SD) range mean (SD) range
1 (n = 32) 32 (11) 13 to 51 11 (16) -7 to 38 11 33%
2 (n = 30) 94 (39) 52 to 189 31 (31) 3 to 148 34 33%
3 (n = 32) 559 (292) 194 to 1236 79 (102) -53 to 452 77 14%
p across tertiles 0.0001Page 3 of 6
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(5%)(p < 0.0001 across ethnic groups).
Table 1 compares the 94 women with serial scans, all with
baseline calcium scores ≥10 Agatston units (Group A),
with women whose baseline calcium scores were <10
Agatston units (Group B). Women in Group A were older,
and more likely to report hypertension, diabetes, current
smoking, and high cholesterol requiring pharmacologic
therapy. Statin use was slightly more prevalent and post-
menopausal estrogen use slightly less prevalent among
women in Group A. Baseline calcium scores for white and
African-American women were 278 ± 330 and 163 ± 214
Agatston units, respectively (p = 0.05).
Annual change in calcium score and age-adjusted change
in calcium score are shown by tertile of calcium score at
baseline (Table 2). Women with higher baseline calcium
scores had greater absolute annual increase in both unad-
justed (79 vs 11 Agatston units/year for women in the
highest vs lowest tertile, p < 0.0001 across tertiles) and
age-adjusted calcium score. Changes in calcium scores
ranged from -53 to +452 Agatston units/year. Annual
change in calcium score did not differ between white and
African-American women (data not shown).
Coronary risk factors are shown by tertile of annual
change in calcium score (Table 3). Body mass index, die-
tary fat consumption and physical activity were not differ-
ent in women with more or less rapid progression of
coronary calcification. Conventional risk factors, includ-
ing age, cigarette smoking and diabetes, also demon-
strated no significant trend across tertiles of progression in
calcium score. Hypertension was reported somewhat
more frequently by women with greater progression of
coronary calcification (33% vs 59% in lowest vs highest
tertile, p = 0.08).
In multiple linear regression analysis, age was not inde-
pendently associated with annual change in calcium score
(Table 4). Statin use was a weak negative predictor of pro-
gression (p = 0.015), whereas calcium score at baseline
Table 3: Risk factors by tertile of annual change in calcium score
Tertile p value
1 2 3
n 32 30 32
mean (SD)
Age, y 64 (7) 65 (7) 67 (12) 0.55
Body mass index 25.1 (4.7) 26 (7.3) 27.1 (6.04) 0.45
% calories from fat 27 (6) 27 (7) 27 (10) 1.00
# days/week moderate-
vigorous exercise
1.8 (2.2) 2.7 (2.6) 2.2 (2) 0.33
%
Hypertension 33 39 59 0.08
Diabetes 7 0 9 0.60*
High cholesterol 16 26 22 0.65
Current smoking 10 10 6 0.63*
Family history premature 
CHD
13 6 19 0.48*
Hormone use at baseline 48 42 44 0.87
Statin use at baseline 13 10 9 0.65*
* Mantel-Hanzel Chi Square used because of small cell sizes
Table 4: Multivariate analysis: Determinants of annual change in calcium score
Parameter estimate 95% CI p value
Age 0.4 -0.83, 1.63 0.52
Baseline calcium score 0.15 0.11, 0.20 <0.0001
Statin use at baseline -43.95 -79.00, -8.88 0.015Page 4 of 6
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cium score (p < 0.0001). Results were similar when hyper-
tension, which had shown a non-significant trend across
tertiles of change in coronary calcium score, was added to
the model. Hypertension itself was not an independent
determinant of progression (data not shown).
Discussion
In this ethnically diverse group of Women's Health Initia-
tive observational study participants, the rate of progres-
sion of coronary calcification was 33%/year among
women with calcium scores between 10 and 190 Agatston
units at baseline, and 14%/year for women with higher
calcium scores. The rate of change in calcium score ranged
widely in individual women, from -53 to +452 Agatston
units/year. In multivariate analysis, statin use was nega-
tively associated with progression of coronary calcifica-
tion, whereas baseline calcium score was a strong and
independent positive predictor of progression.
One strength of this analysis is the inclusion of a wide
range of variables affecting atherosclerotic risk, including
body mass index, physical activity, dietary fat consump-
tion, postmenopausal hormone and statin use in addition
to conventional risk factors. Another strength is the rela-
tively long interval between scans, 3.3 years (mean),
enhancing accuracy of the estimated rate of progression.
This study includes only women, a group traditionally
underrepresented in studies of coronary computed tom-
ography [6,8,9,11], only those with measurable coronary
calcium at baseline, and 37% non-white participants.
Limitations include the sample size and absence of labo-
ratory measures, such as lipids and glucose. These were
performed only in a random 1% subsample of Observa-
tional Study participants, and consequently are not avail-
able for inclusion in this analysis.
The rate of progression of coronary calcification observed
in this analysis is within the range reported by others
[6,9,11]. Similarly, the lack of relationship between post-
menopausal hormone use and progression of coronary
calcification is consistent with prior reports [10,20], as is
the observed inverse association of statin use with pro-
gression of coronary calcification [12,13].
Efforts to identify independent predictors of progression
of coronary calcification have been limited, particularly in
women. A retrospective study of 55 high-risk men identi-
fied baseline calcium score and Lp(a) as independent pre-
dictors of progression in a multivariate model which did
not include statin use [21]. A prospective study of 87 men
and 24 women identified baseline calcium score as a weak
independent predictor (p < 0.05) of change in calcium
score [11]. Smoking, hypertension, diabetes, age, plasma
lipid levels, body mass index, prevalent coronary heart
disease and use of lipid-lowering medications, aspirin,
beta-blockers, angiotensin converting enzyme inhibitors,
calcium antagonists or nitrates were not independent pre-
dictors of progression, although the ability to detect such
relationships was limited in view of the sample size,
which presents a similar limitation in this analysis.
In contrast, smoking was found to be an independent
determinant of progression in a larger study of 311 men
and 184 women, which also identified baseline calcium
score as a potent predictor of progression [7].
Another limitation of this study was use of Agatston score,
rather than calcium volume score. The latter provides bet-
ter reproducibility [22], but was not in widespread use at
the time baseline scans were acquired and was not availa-
ble for the baseline scans in this study. The difference
between Agatston and volumetric scores increases with
the coronary artery calcium score. For example, among
women aged 60–64 years, the 75th percentile has been
reported as 59 Agatston units or 42 volumetric units, and
the 90th percentile as 202 Agatston units or 163 volumet-
ric units [23]. We cannot exclude the possibility that areas
of coronary calcification may have consolidated through
retraction during follow up, a phenomenon which may
not have been accurately assessed using the Agatston
score.
Calcium scores differ in men and women [24]; for exam-
ple the 75th percentile scores for 50–54 year old men and
women are 99 and 3, respectively [4]. For 60–64 year old
men and women, the 75th percentile scores are 247 and
49, respectively. If baseline score is the major determinant
of progression, a gender difference in rates of progression
would be expected on this basis alone. In fact, male gen-
der has been reported as an independent determinant of
progression [7]. Whether rates of progression differ
between men and women after adjustment for baseline
score is uncertain.
Our observations raise several issues with regard to the
potential use of coronary calcium score progression as
either a clinical tool or an outcome for atherosclerotic
intervention trials. First, the variance for this variable is
high, both in our study and in others [7,9,12], limiting, at
least to some extent, its value as a clinical predictor in
individual patients and its appeal as an intermediate out-
come. Second, stratification by statin use should be
considered. Third progression should be adjusted for
baseline calcium score.
Conclusions
In an ethnically diverse cohort of postmenopausal
women with coronary calcium score ≥10 Agatston units,
rates of progression or coronary calcification vary widely.Page 5 of 6
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ated with progression, whereas baseline calcium score was
a strong positive predictor of progression.
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